Summary
Therapy for inpatient burn victims is a clear challenge for the clinician, since directly following injury the pharmacokinetic parameters of many drugs will change drastically. Blood flow to the tissues is decreased; the rate of distribution and elimination of intravenous drugs administered during this time is reduced, and absorption of oral drugs may be slowed. Approximately 48 hours after injury, the blood flow increases, as does internal core temperature: the rates may increase as a result.
Immediately after injury, plasma albumin level rapidly decreases and remains significantly depressed even at 60 days post-burn. Thus, the protein binding of acidic and neutral drugs will decrease and higher amounts of free fraction will be available at the biophase. On the other hand, α1-acid glycoprotein increases in concentration and remains elevated at least 20 days post-burn. Basic drugs exhibit increased protein binding and will most probably need an increased dosage to achieve the appropriate pharmacological effect.
Hepatic metabolism is also affected: the rate of phase I metabolism will decrease, while phase II metabolism is unimpaired and may possibly increase. Other liver functions, such as protein synthesis, are also impaired. The effect on phase I drug metabolism is believed to be due to oxygen-derived free radicals released during the course of injury.
In those patients with full-thickness burns, the epidermal layer is destroyed. Topical drugs have less of a barrier to cross and, consequently, less drug is needed to achieve effectiveness. In addition, the stomach has been found to secrete excess protons which will eventually lead to ulcers in the majority of patients. Hyperchlorhydria may affect the dissolution and disintegration of orally administered drugs in tablet form, as well as the partitioning of the neutral un-ionised species between the stomach and bloodstream. In the small intestine decreased nutrient absorption and DNA synthesis occurs, but the effect this may have on drug absorption is questionable.
This paper focuses on the epidemiology of burn injuries and the way in which the pathophysiology following such injury alters the pharmacokinetics of a drug. Specific examples are provided. Some mention is made of burn management, therapeutic drug monitoring in burn patients, experimental design considerations, and future research topics.
Similar content being viewed by others
References
Aikawa N, Martyn JAJ, Burke JF. Pulmonary artery characterisation and thermodilution cardiac output determination in the management of critically ill burned patients. American Journal of Surgery 135: 811–817, 1978
Anggard E, Jonsson CE. Formation of prostaglandins in the skin following burn injury. In Ramwell & Pharriss (Eds) Prostaglandins in cellular biology, pp. 269–284, Plenum Press, New York, 1972
Arturson G. Pathophysiologic aspects of the burn syndrome. Acta Chirurgica Scandinavica 274(Suppl.): 1–135, 1961
Bloedow DC, Goodfellow LA, Marvin J, Heimbach D. Meperidine disposition in burn patients. Research Communications in Chemical Pathology and Pharmacology 54: 87–99, 1986a
Bloedow DC, Hansbrough JF, Hardin T, Simons M. Postburn scrum drug binding and serum protein concentrations. Journal of Clinical Pharmacology 26: 147–151, 1986b
Boykin Jr JV, Crute SL, Haynes Jr BW. Cimetidine therapy for burn shock: a quantitative assessment. Journal of Trauma 25: 864–870, 1985
Boykin Jr JV. Manson NH. Mechanisms of cimetidine protection following thermal injury. American Journal of Medicine 83(Suppl. 6A): 76–81, 1987
Carter EA, Udall JN, Kirkham SE, Walker WA. Thermal injury and gastrointestinal function. I. Small intestine nutrient absorption and DNA synthesis. Journal of Burn Care and Rehabilitation 7: 469–474, 1986
Chatterjee BF, Barancik JI, Frattianne RB, Waltz RC, Fife D, Northeastern Ohio trauma study: V. Burn injury. Journal of Trauma 26: 844–847, 1986
Ciaccio El, Fruncillo RJ. Decreased aryl hydrocarbon hydroxylase after a 15% burn injury. Biochemical Pharmacology 28: 3151–3152, 1979
Curreri PW. Heck EL. Brown L. et al. Stimulated neutrophil antibacterial function and prediction of wound sepsis in burned patients. Surgery 74: 6. 1973
Czaja A, McAlhany JC. Pruitt BA Acute gastroduodenal disease after thermal injury: an endoscopic evaluation of incidence and natural history. New England Journal of Medicine 29: 925–929, 1976
Czaja AJ, Rizzo TA, Smith WR, Pruitt BA. Acute lier disease after cutaneous thermal injury. Journal of Trauma 15: 887–894, 1975
Daniels JC, Larson DL, Abston S, Ritzmann S. Serum protein profiles in thermal burns. I. Serum electrophoretic patterns, immunoglobulins and transport proteins. Journal of Trauma 14: 137–152, 1974
Demling RH. Burns. New England Journal of Medicine 313: 1389–1398, 1985
Demling RH. Fluid replacement in the burned patient. Surgical Clinics of North America 67(1): 15–30, 1987
Dorr MB. The effect of thermal injury on oxidative drug metabolism. Abstract. Pharmaceutical Research 5(Suppl.): 5–162, 1988
Ecklund J, Granberg P, Liljedahl S. Studies on renal function in burns. Acta Chirurgica Scandinavica 136: 627–640, 1979
Elberg JJ, Scroder HA, Glent-Madsen L, Hall KV, Burns: epidemiology and the effect of a prevention programme. Burns. Including Thermal Injury 13: 391–393, 1987
Florence AT. Attwood D. Physicochemical Principles of Pharmacy. Macmillan Press Ltd, London. 1981
Frolich S. Serum cholinesterase deficiency in major burns. Burns 4: 123–128, 1978
Fruncillo RJ, DiGiregono GJ. The effect of thermal injury on drug metabolism in the rat. Journal of Trauma 23: 523–529, 1983
Fruncillo RJ, DiGregorio GJ. Pharmacokinetics of pentobarbital, quimdine, lidocaine and theophylline in the thermally injured rat. Journal of Pharmaceutical Sciences 73: 1117–1121, 1984
Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clinical Pharmacology and Therapeutics 44: 9–13, 1988
Gault DT, Everitt AS, Gordon PW, Eve MD, Moody FM. Scrum cholinesterase levels after thermal injury. Is treatment required? Burns. Including Thermal Injury 13: 208–212, 1987
Harrison HN, Blackmore WP, Bales HW, Reeder W. The absorption of 14-C labeled sulfamylon acetate through burned skin. I. Experimental methods and initial observations. Journal of Trauma 12: 986–993, 1972
Heidman M. Complement activation by thermal injury and its possible consequences for immune defense. In Ninnemann JL (Ed.) The immune consequences of thermal injury. p. 127 Williams and Wilkins, Baltimore. 1981
Kremer JMH, Wilting J. Janseen LHM Drug binding to alpha 1-acid glycoprotein in health and disease. Pharmacological Reviews 1: 1–48, 1988
Koch-Weser J. Serum drug concentrations in clinical perspective. Therapeutic Drug Monitoring 3: 3–16, 1981
Lee JB, Patak RV, Mookerjee BK. Renal prostaglandins and the regulation of blood pressure and sodium and water homeostasis. American Journal of Medicine 60: 798–816, 1976
Levy Rl, Moskowitz J. Cardiovascular research. Decades of progress, a decade of promise. Science 217: 121–129, 1982
Loirat P, Rohan J, Baillet A, Beaufils F, David R, et al. Increased glomerular filtration in patients with major burns and its effect on the pharmacokinelics of tobramycin. New England Journal of Medicine 299: 915–919, 1978
Lyngdorf P, Occupational burn injuries. Burns. Including Thermal Injury 13: 294–297, 1987
Marathe PH, Dwersteg JR, Pavlin EG, Haschke RH, Heimbach DM, el al. Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. Anesthesiology 70: 752–755, 1989
Marshall Jr WG, Dimick AR. The natural history of major burns with multiple system failure. Journal of Trauma 23: 102–105, 1983
Martin CJ, Wytah R, Muir IF. Exposure treatment in the burned patient: a computer simulation of the thermal environment and its effect on evaporation and heat loss. Clinical Physics and Physiological Measurement 4: 323–326, 1985
Martyn JAJ. Clinical pharmacology and drug therapy in the burned patient. Anesthesiology 65: 67–75, 1986
Martyn JAJ, Goldhill DR, Goudsouzian NG. Clinical pharmacology of muscle relaxants in patients with burn injury. Journal of Clinical Pharmacology 26: 680–685, 1986
Martyn JAJ, Greenblatt DJ. Lorazepam conjugation is unimpaired in burn trauma. Clinical Pharmacology and Therapeutics 43: 250–255, 1988
Martyn JAJ, Greenblatt DJ, Abernathy DR. Increased cimetidine clearance in burn patients. Journal of the American Medical Association 253: 1288–1291, 1985
Martyn JAJ, Greenblatl DJ, Hagen J, Hoaglin DC. Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. European Journal of Clinical Pharmacology 36: 361–367, 1989
Martyn JAJ, Greenblatt DJ, Quinby WC. Diazepam kinetics following burns. Anesthesia and Analgesia 62: 293–297, 1983
Merrell SW, Saffle JR, Sullivan JJ, Larsen CM, Warden GD, Increased survival after major thermal injury. A nine-year review. American Journal of Surgery 154: 623–627, 1987
Moran K. Munster AM. Alterations of the host defense mechanism in burned patients. Surgical Clinics of North America 67(1): 47–56, 1987
Munster AM. Immunologie alterations following injury. Advances in Orthopaedic Surgery 328: 1985
Notan RE. Biopharmaceutics and clinical pharmacokinetics, 3rd ed., pp. 119–149, Marcell Dekker Inc., New York. 1980
O’Neill JA. Pruitt BA. Moncrief JA. Studies of renal function during early poslburn period. Presented at the Third International Congress on Research. Burns. Prague. September 20-25, 1970
Overman JA. Carrithers JA. Quantitative alterations in lymphocyte subpopulations in burn patients Clinical and Laboratory Science 2: 52–55, 1989
Pegg SP, Miller PM, Sticklen EJ, Storie WJ, Epidemiology of industrial burns in Brisbane. Burns. Including Thermal Injury 12: 484–490, 1986
Perry S, Inturrisi CE. Analgesia and morphine disposition in burn patients. Journal of Burn Care and Rehabilitation 4: 276–279, 1983
Pippenger CE. Massoud N. Therapeutic drug monitoring. In Benet et al. (Eds) Pharmacokinetic basis for drug treatment, pp. 367–393, Raven Press, New York. 1984
Polk HC. Consensus summary on infection. Journal of Trauma 19: 894. 1979
Pond SM. Pharmacokinetic drug interactions. In Benet et al. (Eds) Pharmacokinetic basis for drug treatment, pp. 195–220, Raven Press, New York. 1984
Pruitt BA. Fluid and electrolyte replacement in the bumed patient. Surgical Clinics of North America 12: 1291–1312, 1978
Punch JD, Smith DJ, Robson MC. Hospital care of major burns. Postgraduate Medicine 85: 205–215, 1989
Rossignol AM, Locke JA, Boyle CM, Burke JF. Epidemiology of work-related burn injuries in Massachusetts requiring hospitalization. Journal of Trauma 26: 1097–1101, 1986
Rossman I. Clinical geriatrics. 2nd ed., pp. 23–52, 132-137, 224-229, JB Lippincott, Philadelphia. 1979
Sawchuk RJ, Rector TS. Drug kinetics in burn patients. Clinical Pharmacokinelics 5: 548–556, 1980
Wachtel TL. Major burns. Postgraduate Medicine 85: 178–196, 1989
Walstad RA, Aanderud L, Thurmann-Nielson E. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. European Journal of Clinical Pharmacology 35: 543–549, 1988
Waxman K, Rebello T, Pinderski L, O’Neal K, Khan N, et al. Protein loss across burn wounds. Journal of Trauma 27: 136–140, 1987
Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effect of severe burn injury on substrate cycling by glucose and fatty acids. New England Journal of Medicine 317: 403–408, 1987
Zaske DE, Sawchuk RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamycin in burn patients. Journal of Trauma 16: 824–828, 1976
Zaske DE, Sawchuk RJ, Strate RG. The necessity of increased doses of amikacin in burn patients. Surgery 84: 603–608, 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bonate, P.L. Pathophysiology and Pharmacokinetics Following Burn Injury. Clin Pharmacokinet 18, 118–130 (1990). https://doi.org/10.2165/00003088-199018020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199018020-00003